Skip to main content

Hemispherx BioPharma, Inc (NYSEAMEX:HEB) Investor Lawsuit Against Directors Over Alleged Breaches Of Fiduciary Duties Filed

  • If you are a current long term stockholder in Hemispherx BioPharma, Inc (NYSEAMEX:HEB) shares, you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Site Members can sign up for company wide alerts

Lawsuit Overview

April 30, 2013 (Shareholders Foundation) - An investor in shares of Hemispherx BioPharma, Inc (NYSEAMEX:HEB) filed a lawsuit against certain officers and directors over alleged breaches of fiduciary duties in connection with certain statements made in regards to Hemispherx BioPharma’s new drug Ampligen. The plaintiff alleges that the defendants misrepresented the safety and efficacy ...



You must register (for free) or login to view the entire case.